To test our hypothesis, we aim to explore the possible therapeutic efficacy of P-MSCs using WNIN/GR-Ob (Ob-T2D) rats studied in both subcutaneous and visceral depots and compare them with WNIN/Controls to evaluate) glycaemic status (IGTT, ITT, HOMA-IR), cytokine profiling, insulin signaling, metabolites, and Glut4 transportation and translocation. The gene discussed is SLC2A4; the disease is type 2 diabetes mellitus.